Effectiveness of prevention strategies for contrast-induced nephropathy a systematic review and meta-analysis

Annals of Internal Medicine

Volumn 164, Issue 6, 2016, Pages 406-416

  Subramaniam, Rathan M ^a   Suarez Cuervo, Catalina ^b   Wilson, Renee F ^b   Turban, Sharon ^a   Zhang, Allen ^b   Sherrod, Cheryl ^b   Aboagye, Jonathan ^b   Eng, John ^a   Choi, Michael J ^a   Hutfless, Susan ^a   Bass, Eric B ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ASCORBIC ACID; BICARBONATE; CONTRAST MEDIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SODIUM CHLORIDE; ANTIOXIDANT; SCAVENGER;

COCHRANE LIBRARY; COMPARATIVE EFFECTIVENESS; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; DATA BASE; DATA EXTRACTION; EMBASE; HUMAN; LOW DRUG DOSE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASES; ODDS RATIO; UNITED STATES;

ACETYLCYSTEINE; ANTIOXIDANTS; ASCORBIC ACID; CONTRAST MEDIA; FREE RADICAL SCAVENGERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; ODDS RATIO; SODIUM BICARBONATE; SODIUM CHLORIDE; UNITED STATES;

EID: 84960898146     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-1456     Document Type: Review

References (115)

1. Kitajima K, Maeda T, Watanabe S, Sugimura K. Recent issues in contrast-induced nephropathy. Int J Urol. 2011; 18: 686-90. [PMID: 21834851] doi: 10.1111/j.1442-2042.2011.02830.x
2. Nash K, Hafeez A, Hou S. Hospital-Acquired renal insufficiency. Am J Kidney Dis. 2002; 39: 930-6. [PMID: 11979336]
3. Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S., et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004; 93: 1515-9. [PMID: 15194023]
4. Davenport MS, Cohan RH, Ellis JH. Contrast media controversies in 2015: imaging patients with renal impairment or risk of contrast reaction. AJR Am J Roentgenol. 2015; 204: 1174-81. [PMID: 25730301] doi: 10.2214/AJR.14.14259
5. Subramanian S, Tumlin J, Bapat B, Zyczynski T. Economic burden of contrast-induced nephropathy: implications for prevention strategies. J Med Econ. 2007; 10: 119-34. [PMID: 19702434] doi: 10.3111/200710119134
6. Singh N, Lee JZ, Huang JJ, Low SW, Howe C, Pandit A., et al. Benefit of statin pretreatment in prevention of contrast-induced nephropathy in different adult patient population: systematic review and meta-Analysis. Open Heart. 2014; 1: e000127. [PMID: 25332824] doi: 10.1136/openhrt-2014-000127
7. Sun Z, Fu Q, Cao L, Jin W, Cheng L, Li Z. Intravenous N-Acetylcysteine for prevention of contrast-induced nephropathy: a meta-Analysis of randomized, controlled trials. PLoS One. 2013; 8: e55124. [PMID: 23383076] doi: 10.1371/journal.pone.0055124
8. Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim TH., et al. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury a systematic review and meta-Analysis. Circ J. 2012; 76: 2255-65. [PMID: 22975638]
9. Zhang B, Liang L, Chen W, Liang C, Zhang S. The efficacy of sodium bicarbonate in preventing contrast-induced nephropathy in patients with pre-existing renal insufficiency: a meta-Analysis. BMJ Open. 2015; 5: e006989. [PMID: 25783425] doi: 10.1136/bmjopen -2014-006989
10. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Metaanalysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008; 148: 284-94. [PMID: 18283206]
11. Sadat U, Usman A, Gillard JH, Boyle JR. Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-Analysis of randomized, controlled trials. J Am Coll Cardiol. 2013; 62: 2167-[PMID: 23994417] doi: 10.1016/j.jacc.2013.07.065
12. Subramaniam RM, Wilson RF, Turban S, Suarez-Cuervo C, Zhang A, Sherrod C., et al. Contrast-Induced Nephropathy: Comparative Effectiveness of Measures to Prevent Contrast-Induced Nephropathy. Evidence Report no. 156. (Prepared by the Johns Hopkins University Evidence-based Practice Center under contract 290-2012-00007I.) AHRQ Publication no. 15-EHC023-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2015
13. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication no. 10(14)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2014. Accessed at http://effectivehealthcare. ahrq.gov/index.cfm/search-for-guides-reviews-And-reports/?pageaction=displayproduct&productid=318 on 17 December 2015
14. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D., et al. GRADE guidelines 6. Rating the quality of evidence- imprecision. J Clin Epidemiol. 2011; 64: 1283-93. [PMID: 21839614] doi: 10.1016/j.jclinepi.2011.01.012
15. Cornell JE, Mulrow CD, Localio R, Stack CB, Meibohm AR, Guallar E., et al. Random-effects meta-Analysis of inconsistent effects: a time for change. Ann Intern Med. 2014; 160: 267-70. [PMID: 24727843]
16. Hölscher B, Heitmeyer C, Fobker M, Breithardt G, Schaefer RM, Reinecke H. Predictors for contrast media-induced nephropathy and long-term survival: prospectively assessed data from the randomized controlled Dialysis-Versus-Diuresis (DVD) trial. Can J Cardiol. 2008; 24: 845-50. [PMID: 18987758]
17. Reinecke H, Fobker M, Wellmann J, Becke B, Fleiter J, Heitmeyer C., et al. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-Acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial. Clin Res Cardiol. 2007; 96: 130-9. [PMID: 17180572]
18. Kotlyar E, Keogh AM, Thavapalachandran S, Allada CS, Sharp J, Dias L., et al. Prehydration alone is sufficient to prevent contrastinduced nephropathy after day-only angiography procedures-A randomised controlled trial. Heart Lung Circ. 2005; 14: 245-51. [PMID: 16360994]
19. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A., et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003; 289: 553-8. [PMID: 12578487]
20. Traub SJ, Mitchell AM, Jones AE, Tang A, O'Connor J, Nelson T., et al. N-Acetylcysteine plus intravenous fluids versus intravenous fluids alone to prevent contrast-induced nephropathy in emergency computed tomography. Ann Emerg Med. 2013; 62: 511-520.e25. [PMID: 23769807] doi: 10.1016/j.annemergmed.2013.04.012
21. Thayssen P, Lassen JF, Jensen SE, Hansen KN, Hansen HS, Christiansen EH., et al. Prevention of contrast-induced nephropathy with N-Acetylcysteine or sodium bicarbonate in patients with ST-segmentmyocardial infarction: a prospective, randomized, open-labeled trial. Circ Cardiovasc Interv. 2014; 7: 216-24. [PMID: 24714489] doi: 10 .1161/CIRCINTERVENTIONS.113.000653
22. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011; 124: 1250-9. [PMID: 21859972] doi: 10.1161/CIRCULATIONAHA.111 .038943
23. Alioglu E, Saygi S, Turk U, Kirilmaz B, Tuzun N, Duman C., et al. N-Acetylcysteine in preventing contrast-induced nephropathy assessed by cystatin C. Cardiovasc Ther. 2013; 31: 168-73. [PMID: 22212518] doi: 10.1111/j.1755-5922.2011.00309.x
24. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y., et al. Prospective randomized study of N-Acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv. 2002; 57: 279-83. [PMID: 12410497]
25. Amini M, Salarifar M, Amirbaigloo A, Masoudkabir F, Esfahani F. N-Acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial. Trials. 2009; 10: 45. [PMID: 19563648] doi: 10.1186/1745-6215-10-45
26. Aslanger E, Uslu B, Akdeniz C, Polat N, Cizgici Y, Oflaz H. Intrarenal application of N-Acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty. Coron Artery Dis. 2012; 23: 265-70. [PMID: 22343798] doi: 10.1097/MCA .0b013e328351aacc
27. Awal A, Ahsan SA, Siddique MA, Banerjee S, Hasan MI, Zaman SM., et al. Effect of hydration with or without n-Acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention. Mymensingh Med J. 2011; 20: 264-9. [PMID: 21522098]
28. Azmus AD, Gottschall C, Manica A, Manica J, Duro K, Frey M., et al. Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Invasive Cardiol. 2005; 17: 80-4. [PMID: 15687530]
29. Baskurt M, Okcun B, Abaci O, Dogan GM, Kilickesmez K, Ozkan AA., et al. N-Acetylcysteine versus N-Acetylcysteine + theophylline for the prevention of contrast nephropathy. Eur J Clin Invest. 2009; 39: 793-9. [PMID: 19500141] doi: 10.1111/j.1365-2362.2009.02173.x
30. Boccalandro F, Amhad M, Smalling RW, Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv. 2003; 58: 336-41. [PMID: 12594698]
31. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G., et al. Acetylcysteine and contrast agent-Associated nephrotoxicity. J Am Coll Cardiol. 2002; 40: 298-303. [PMID: 12106935]
32. Brueck M, Cengiz H, Hoeltgen R, Wieczorek M, Boedeker RH, Scheibelhut C., et al. Usefulness of N-Acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial. J Invasive Cardiol. 2013; 25: 276-83. [PMID: 23735352]
33. Carbonell N, Blasco M, Sanjuán R, Pérez-Sancho E, Sanchis J, Insa L., et al. Intravenous N-Acetylcysteine for preventing contrastinduced nephropathy: a randomised trial. Int J Cardiol. 2007; 115: 57- [PMID: 16814414]
34. Carbonell N, Sanjuán R, Blasco M, JordáA, Miguel A. N-Acetylcysteine: short-term clinical benefits after coronary angiography in high-risk renal patients. Rev Esp Cardiol. 2010; 63: 12-9. [PMID: 20089221]
35. Castini D, Lucreziotti S, Bosotti L, Salerno Uriarte D, Sponzilli C, Verzoni A., et al. Prevention of contrast-induced nephropathy: a single center randomized study. Clin Cardiol. 2010; 33: E63-8. [PMID: 20127900] doi: 10.1002/clc.20576
36. Demir M, Kutlucan A, Akin H, Aydin O, Sezer MT. Comparison of different agents on radiographic contrast agent induced nephropathy. European Journal of General Medicine. 2008; 5: 222-7
37. Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J., et al. A randomized controlled trial of N-Acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002; 62: 2202-7. [PMID: 12427146]
38. Erturk M, Uslu N, Gorgulu S, Akbay E, Kurtulus G, Akturk IF., et al. Does intravenous or oral high-dose N-Acetylcysteine in addition to saline prevent contrast-induced nephropathy assessed by cystatin C?. Coron Artery Dis. 2014; 25: 111-7. [PMID: 24365793] doi: 10.1097/MCA.0000000000000073
39. Ferrario F, Barone MT, Landoni G, Genderini A, Heidemperger M, Trezzi M., et al. Acetylcysteine and non-ionic isosmolar contrastinduced nephropathy-A randomized controlled study. Nephrol Dial Transplant. 2009; 24: 3103-7. [PMID: 19549691] doi: 10.1093/ndt/gfp306
40. Goldenberg I, Shechter M, Matetzky S, Jonas M, Adam M, Pres H., et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J. 2004; 25: 212-8. [PMID: 14972421]
41. Gomes VO, Poli De Figueredo CE, Caramori P, Lasevitch R, Bodanese LC, Arau?jo A., et al. N-Acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart. 2005; 91: 774-8. [PMID: 15894775]
42. Gulel O, Keles T, Eraslan H, Aydogdu S, Diker E, Ulusoy V. Prophylactic acetylcysteine usage for prevention of contrast nephropathy after coronary angiography. J Cardiovasc Pharmacol. 2005; 46: 464-7. [PMID: 16160598]
43. Günebakmaz O, Kaya MG, Koc F, Akpek M, Kasapkara A, Inanc MT., et al. Does nebivolol prevent contrast-induced nephropathy in humans?. Clin Cardiol. 2012; 35: 250-4. [PMID: 22262230] doi: 10 .1002/clc.21013
44. Hsu CH, Lee JD, Lo PH, Lin JJ, Chang HW, Chou HT. Prevention of radiocontrast-induced nephropathy with N-Acetylcysteine after cardiac angiography in diabetic patients with renal dysfunction. Mid- Taiwan Journal of Medicine. 2007; 12: 173-83
45. Hsu TF, Huang MK, Yu SH, Yen DH, Kao WF, Chen YC., et al. N-Acetylcysteine for the prevention of contrast-induced nephropathy in the emergency department. Intern Med. 2012; 51: 2709-14. [PMID: 23037460]
46. Izani Wan Mohamed WM, Darus Z, Yusof Z. Oral N-Acetylcysteine in prevention of contrast induced nephropathy following coronary angiogram. International Medical Journal. 2008; 15: 353-61
47. Jaffery Z, Verma A, White CJ, Grant AG, Collins TJ, Grise M.A., et al. A randomized trial of intravenous N-Acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes. Catheter Cardiovasc Interv. 2012; 79: 921-6. [PMID: 21542122] doi: 10 .1002/ccd.23157
48. Kama A, Yilmaz S, Yaka E, Dervisoglu E, Dogan NÖ, Erimsah E., et al. Comparison of short-term infusion regimens of N-Acetylcysteine plus intravenous fluids, sodium bicarbonate plus intravenous fluids, and intravenous fluids alone for prevention of contrast-induced nephropathy in the emergency department. Acad Emerg Med. 2014; 21: 615-22. [PMID: 25039544] doi: 10.1111/acem .12400
49. Kefer JM, Hanet CE, Boitte S, Wilmotte L, De Kock M. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient?. Acta Cardiol. 2003; 58: 555-60. [PMID: 14713182]
50. Khalili H, Dashti-Khavidaki S, Tabifar H, Ahmadinejad N, Ahmadi F. N-Acetylcysteine in the prevention of contrast agent-induced nephrotoxicity in patients undergoing computed tomography studies. Therapy. 2006; 3: 773-7
51. Kim BJ, Sung KC, Kim BS, Kang JH, Lee KB, Kim H., et al. Effect of N-Acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial. Int J Cardiol.2010; 138: 239-45.[PMID: 18793808]doi: 10.1016/j.ijcard .2008.08.013
52. Kimmel M, Butscheid M, Brenner S, Kuhlmann U, Klotz U, Alscher DM. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-Acetylcysteine or zinc-preliminary results. Nephrol Dial Transplant. 2008; 23: 1241-5. [PMID: 18174269] doi: 10.1093/ndt/gfm785
53. Kinbara T, Hayano T, Ohtani N, Furutani Y, Moritani K, Matsuzaki M. Efficacy of N-Acetylcysteine and aminophylline in preventing contrast-induced nephropathy. J Cardiol. 2010; 55: 174-9. [PMID: 20206069] doi: 10.1016/j.jjcc.2009.10.006CIN = contrast-induced nephropathy
54. MacNeill BD, Harding SA, Bazari H, Patton KK, Colon-Hernadez P, DeJoseph D., et al. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv. 2003; 60: 458-61. [PMID: 14624421]
55. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M., et al. N-Acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006; 354: 2773-82. [PMID: 16807414]
56. Miner SE, Dzavik V, Nguyen-Ho P, Richardson R, Mitchell J, Atchison D., et al. N-Acetylcysteine reduces contrast-Associated nephropathy but not clinical events during long-term follow-up. Am Heart J. 2004; 148: 690-5. [PMID: 15459602]
57. Ochoa A, Pellizzon G, Addala S, Grines C, Isayenko Y, Boura J., et al. Abbreviated dosing of N-Acetylcysteine prevents contrastinduced nephropathy after elective and urgent coronary angiography and intervention. J Interv Cardiol. 2004; 17: 159-65. [PMID: 15209578]
58. Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J. 2003; 146: E23. [PMID: 14661012]
59. Ozcan EE, Guneri S, Akdeniz B, Akyildiz IZ, Senaslan O, Baris N., et al. Sodium bicarbonate, N-Acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J. 2007; 154: 539-44. [PMID: 17719303]
60. Poletti PA, Saudan P, Platon A, Mermillod B, Sautter AM, Vermeulen B., et al. I.V. N-Acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol. 2007; 189: 687-92. [PMID: 17715118]
61. Rashid ST, Salman M, Myint F, Baker DM, Agarwal S, Sweny P., et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of in- travenous N-Acetylcysteine. J Vasc Surg. 2004; 40: 1136-41. [PMID: 15622367]
62. Ratcliffe JA, Thiagarajah P, Chen J, Kavala G, Kanei Y, Fox J., et al. Prevention of contrast-induced nephropathy: A randomized controlled trial of sodium bicarbonate and N-Acetylcysteine. Int J Angiol. 2009; 18: 193-7. [PMID: 22477552]
63. Sadat U, Walsh SR, Norden AG, Gillard JH, Boyle JR. Does oral N-Acetylcysteine reduce contrast-induced renal injury in patients with peripheral arterial disease undergoing peripheral angiography?. A randomized-controlled study. Angiology. 2011; 62: 225-30. [PMID: 20682612] doi: 10.1177/0003319710377078
64. Seyon RA, Jensen LA, Ferguson IA, Williams RG. Efficacy of N-Acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention. Heart Lung. 2007; 36: 195-204. [PMID: 17509426]
65. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002; 40: 1383-8. [PMID: 12392825]
66. Tanaka A, Suzuki Y, Suzuki N, Hirai T, Yasuda N, Miki K., et al. Does N-Acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction?. Intern Med. 2011; 50: 673-7. [PMID: 21467697]
67. Tepel M, Van Der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-Agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000; 343: 180-4. [PMID: 10900277]
68. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G., et al. Impact of high-dose N-Acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol. 2010; 55: 2201-9. [PMID: 20466200] doi: 10.1016/j.jacc.2009.08.091
69. Yeganehkhah MR, Iranirad L, Dorri F, Pazoki S, Akbari H, Miryounesi M., et al. Comparison between three supportive treatments for prevention of contrast-induced nephropathy in high-risk patients undergoing coronary angiography. Saudi J Kidney Dis Transpl. 2014; 25: 1217-23. [PMID: 25394438]
70. Beyazal H, Caliskan Z, Utac? C. Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast-induced nephropathy. Ren Fail. 2014; 36: 351-5. [PMID: 24341598] doi: 10.3109/0886022X.2013.866016
71. Boucek P, Havrdova T, Oliyarnyk O, Skibova J, Pecenkova V, Pucelikova T., et al. Prevention of contrast-induced nephropathy in diabetic patients with impaired renal function: a randomized, double blind trial of sodium bicarbonate versus sodium chloride-based hydration. Diabetes Res Clin Pract. 2013; 101: 303-8. [PMID: 23835495] doi: 10.1016/j.diabres.2013.05.015
72. Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N., et al. Sodium bicarbonate vs. sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008; 300: 1038-46. [PMID: 18768415] doi: 10.1001/jama.300.9.1038
73. Gomes VO, Lasevitch R, Lima VC, Brito FS Jr, Perez-Alva JC, Moulin B., et al. Hydration with sodium bicarbonate does not prevent contrast nephropathy: a multicenter clinical trial. Arq Bras Cardiol. 2012; 99: 1129-34. [PMID: 23184077]
74. Koc F, Ozdemir K, Altunkas F, Celik A, Dogdu O, Karayakali M., et al. Sodium bicarbonate versus isotonic saline for the prevention of contrast-induced nephropathy in patients with diabetes mellitus undergoing coronary angiography and/or intervention: a multicenter prospective randomized study. J Investig Med. 2013; 61: 872-7. [PMID: 23552179] doi: 10.231/JIM.0b013e31828e9cab
75. Kooiman J, Sijpkens YW, De Vries JP, Brulez HF, Hamming JF, Van Der Molen AJ., et al. A randomized comparison of 1-h sodium bicarbonate hydration versus standard peri-procedural saline hydration in patients with chronic kidney disease undergoing intravenous contrast-enhanced computerized tomography. Nephrol Dial Transplant. 2014; 29: 1029-36. [PMID: 24578471] doi: 10.1093/ndt/gfu025
76. Lee SW, Kim WJ, Kim YH, Park SW, Park DW, Yun SC., et al. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial). Am J Cardiol. 2011; 107: 1447-52. [PMID: 21420063] doi: 10.1016/j.amjcard .2011.01.019
77. Manari A, Magnavacchi P, Puggioni E, Vignali L, Fiaccadori E, Menozzi M., et al. Acute kidney injury after primary angioplasty: effect of different hydration treatments. J Cardiovasc Med (Hagerstown). 2014; 15: 60-7. [PMID: 24500238] doi: 10.2459/JCM .0b013e3283641bb8
78. Masuda M, Yamada T, Mine T, Morita T, Tamaki S, Tsukamoto Y., et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol. 2007; 100: 781-6. [PMID: 17719320]
79. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ., et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004; 291: 2328-34. [PMID: 15150204]
80. Motohiro M, Kamihata H, Tsujimoto S, Seno T, Manabe K, Isono T., et al. A new protocol using sodium bicarbonate for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography.AmJ Cardiol. 2011; 107: 1604-8. [PMID: 21420053] doi: 10.1016/j.amjcard.2011.01.045
81. Ueda H, Yamada T, Masuda M, Okuyama Y, Morita T, Furukawa Y., et al. Prevention of contrast-induced nephropathy by bolus injection of sodium bicarbonate in patients with chronic kidney disease undergoing emergent coronary procedures. Am J Cardiol. 2011; 107: 1163-7. [PMID: 21349483] doi: 10.1016/j.amjcard.2010.12.012
82. Vasheghani-Farahani A, Sadigh G, Kassaian SE, Khatami SM, Fotouhi A, Razavi SA., et al. Sodium bicarbonate in preventing contrast nephropathy in patients at risk for volume overload: a randomized controlled trial. J Nephrol. 2010; 23: 216-23. [PMID: 20175053]
83. Heguilén RM, Liste AA, Payaslian M, Ortemberg MG, Albarracín LM, Bernasconi AR. N-Acethyl-cysteine reduces the occurrence of contrast-induced acute kidney injury in patients with renal dysfunction: a single-center randomized controlled trial. Clin Exp Nephrol. 2013; 17: 396-404. [PMID: 23138396] doi: 10.1007/s10157-012-0722-3
84. Gueler F, Rong S, Park JK, Fiebeler A, Menne J, Elger M., et al. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol. 2002; 13: 2288-98. [PMID: 12191973]
85. Han Y, Zhu G, Han L, Hou F, Huang W, Liu H., et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J AmColl Cardiol. 2014; 63: 62-70. [PMID: 24076297] doi: 10.1016/j.jacc.2013 .09.017
86. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ., et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-A randomized controlled study. Am Heart J. 2008; 155: 499.e1-8. [PMID: 18294484] doi: 10 .1016/j.ahj.2007.11.042
87. Li W, Fu X, Wang Y, Li X, Yang Z, Wang X., et al. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology. 2012; 122: 195-202. [PMID: 22854323] doi: 10.1159/000339472
88. Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D'Ambrosio A., et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage dur- ing angioplasty-contrast-induced nephropathy] trial. Am J Cardiol. 2011; 108: 1-7. [PMID: 21529740] doi: 10.1016/j.amjcard.2011.03 .001
89. Abaci O, Arat Ozkan A, Kocas C, Cetinkal G, Sukru Karaca O, Baydar O., et al. Impact of Rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography. Am J Cardiol. 2015; 115: 867-71. [PMID: 25670636] doi: 10.1016/j.amjcard.2015.01.007
90. Qiao B, Deng J, Li Y, Wang X, Han Y. Rosuvastatin attenuated contrast-induced nephropathy in diabetes patients with renal dysfunction. Int J Clin Exp Med. 2015; 8: 2342-9. [PMID: 25932171]
91. Sanei H, Hajian-Nejad A, Sajjadieh-Kajouei A, Nazemzadeh N, Alizadeh N, Bidram P., et al. Short term high dose atorvastatin for the prevention of contrast-induced nephropathy in patients undergoing computed tomography angiography. ARYA Atheroscler. 2014; 10: 252-8
92. Yun KH, Lim JH, Hwang KB, Woo SH, Jeong JW, Kim YC., et al. Effect of high dose rosuvastatin loading before percutaneous coronary intervention on contrast-induced nephropathy. Korean Circ J. 2014; 44: 301-6. [PMID: 25278982] doi: 10.4070/kcj.2014.44.5.301
93. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol. 2014; 63: 71-9. [PMID: 24076283] doi: 10.1016/j.jacc.2013.04.105
94. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C., et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology. 2010; 61: 711-4. [PMID: 20395226] doi: 10 .1177/0003319710364216
95. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C., et al. Usefulness of atorvastatin (80 mg) in prevention of contrastinduced nephropathy in patients with chronic renal disease. Am J Cardiol. 2010; 105: 288-92. [PMID: 20102936] doi: 10.1016/j.amjcard .2009.09.026
96. Shehata M, Hamza M. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial. Cardiovasc Ther. 2015; 33: 35-41. [PMID: 25677920] doi: 10.1111/1755-5922.12108
97. Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B., et al. Impact of a high loading dose of atorvastatin on contrastinduced acute kidney injury. Circulation. 2012; 126: 3008-16. [PMID: 23147173] doi: 10.1161/CIRCULATIONAHA.112.103317
98. Li H, Li X, Ma H, Wang Y, Fu N, Jin D., et al. Atorvastatin combining with probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure. Scientific- WorldJournal. 2014; 2014: 565367. [PMID: 24672331] doi: 10.1155/2014/565367
99. Han S, Li XM, Mohammed Ali LA, Fu NK, Jin DX, Cong HL. Effect of short-term different statins loading dose on renal function and CI-AKI incidence in patients undergoing invasive coronary procedures [Letter]. Int J Cardiol. 2013; 168: 5101-3. [PMID: 23972962] doi: 10.1016/j.ijcard.2013.07.252
100. Jo SH, Hahn JY, Lee SY, Kim HJ, Song YB, Choi JH., et al. Highdose atorvastatin for preventing contrast-induced nephropathy in primary percutaneous coronary intervention. J Cardiovasc Med (Hagerstown). 2015; 16: 213-9. [PMID: 25032713] doi: 10.2459/JCM .0000000000000157
101. Kaya A, Kurt M, Tanboga IH, Isik T, Ekinci M, Aksakal E., et al. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial). Acta Cardiol. 2013; 68: 489-94. [PMID: 24283110]
102. Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F., et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2009; 104: 519-24. [PMID: 19660605] doi: 10.1016/j.amjcard .2009.04.014
103. Liu Y, Liu YH, Tan N, Chen JY, Zhou YL, Li LW., et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention. PLoS One. 2014; 9: e111124. [PMID: 25357250] doi: 10.1371/journal.pone.0111124
104. Zhang J, Li Y, Tao GZ, Chen YD, Hu TH, Cao XB., et al. Shortterm rosuvastatin treatment for the prevention of contrast-induced acute kidney injury in patients receiving moderate or high volumes of contrast media: a sub-Analysis of the TRACK-D study. Chin Med J (Engl). 2015; 128: 784-9. [PMID: 25758273] doi: 10.4103/0366-6999 .152620
105. Acikel S, Muderrisoglu H, Yildirir A, Aydinalp A, Sade E, Bayraktar N., et al. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagul Fibrinolysis. 2010; 21: 750-7. [PMID: 20962623] doi: 10.1097/MBC .0b013e32834014a4
106. Boscheri A, Weinbrenner C, Botzek B, Reynen K, Kuhlisch E, Strasser RH. Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction. Clin Nephrol. 2007; 68: 279-86. [PMID: 18044259]
107. Dvorsak B, Kanic V, Ekart R, Bevc S, Hojs R. Ascorbic Acid for the prevention of contrast-induced nephropathy after coronary angiography in patients with chronic renal impairment: a randomized controlled trial. Ther Apher Dial. 2013; 17: 384-90. [PMID: 23931876] doi: 10.1111/1744-9987.12083
108. Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Iacovis P, Greenwood DC., et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004; 110: 2837-42. [PMID: 15492300]
109. Zhou L, Chen H. Prevention of contrast-induced nephropathy with ascorbic acid. Intern Med. 2012; 51: 531-5. [PMID: 22449658]
110. Albabtain MA, Almasood A, Alshurafah H, Alamri H, Tamim H. Efficacy of ascorbic acid, N-Acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study. J Interv Cardiol. 2013; 26: 90-6. [PMID: 22994682] doi: 10.1111/j.1540-8183.2012.00767.x
111. Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A., et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007; 115: 1211-7. [PMID: 17309916]
112. Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL., et al. N-Acetylcysteine versus AScorbic acid for preventing contrast- Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-A prospective randomized controlled trial. Am Heart J. 2009; 157: 576-83. [PMID: 19249432] doi: 10 .1016/j.ahj.2008.11.010
113. Vidt DG, Harris S, McTaggart F, Ditmarsch M, Sager PT, Sorof JM. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol. 2006; 97: 1602-6. [PMID: 16728222]
114. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al; ACCF. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2012; 79: 453-95. [PMID: 22328235] doi: 10.1002/ccd.23438
115. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012; 2: 1-138